TREAT NL (TREatment of ATopic Eczema, the Netherlands) Registry: Dutch National Registry for Patients With Moderate-to-severe Atopic Eczema on Photo- or Systemic Therapies
TREAT NL (TREatment of ATopic Eczema, the Netherlands) Registry: Dutch National Registry for Patients With Moderate-to-severe Atopic Eczema on Photo- or Systemic Therapies
The TREAT NL (TREatment of ATopic eczema, the Netherlands) registry is a national registry
 for children and adults with moderate-to-severe atopic eczema aiming to gather data on their
 prescribed photo- and systemic immunomodulating therapies. Atopic eczema is a common,
 chronic, itchy, inflammatory skin disease that can have a major impact on the quality of life
 of patients and their immediate surroundings.

 Serious atopic eczema patients are treated by means of photo- or systemic immunomodulating
 therapy. Of these mostly off-label applied therapies, there is insufficient evidence on the
 short and long term for their effectiveness, safety and cost-effectiveness. Moreover, good
 comparative research and real-life data are lacking. With the arrival of new expensive
 treatments it is crucial to get insight into these treatments in order to improve quality of
 care.

 By means of a prospective registry these data can be collected and help to obtain information
 for clinical practice, for answering research questions, for reducing costs and implementing
 the results by guidelines and decision aids.
Inclusion Criteria:

 -  Patient has a diagnosis of atopic eczema, based on the U.K. working party's diagnostic
 criteria;

 -  Starts with any type of phototherapy (e.g. UVB) or systemic immunomodulating therapy
 (e.g. cyclosporin, systemic glucocorticosteroids, azathioprine, methotrexate,
 mycophenolic acid, dupilumab);

 -  Has voluntarily signed and dated an informed consent prior to any study related
 procedure or has a legal representative to do so and is willing to comply with the
 requirements of this study protocol.

 Exclusion Criteria:

 -  Patient uses only (systemic) antibiotics or antihistamines;

 -  Patient starts with systemic immunomodulating therapy for another indication than
 atopic eczema;

 -  Insufficient understanding of the study by the patient or parent/legal representative.